Daily Pharma News - 25 October 2026

Welcome to today's daily pharma news roundup for pharmacy students. Today's stories span India and the world, from a new government review of pharmaceutical marketing rules and a CDSCO spurious drug alert, to a first-of-its-kind cancer blood test approval in Pune, a tragic industrial accident in Telangana, new cancer trial data from China, a patent licence ruling in Russia, and a sobering safety disclosure from a global cell therapy trial. Together, they show how regulation, drug safety, diagnostics, industrial safety, and clinical research shape everyday pharmacy practice.

India pharma marketing rules review: Centre sets up panel to examine UCPMP 2024 and unethical practices

The Department of Pharmaceuticals has set up a three-member panel led by NITI Aayog's M Srinivas to review pharmaceutical marketing practices in India, including the Uniform Code of Pharmaceutical Marketing Practices (UCPMP) 2024. The panel is expected to report within two months of its first meeting. The move puts the spotlight on how medicines are promoted to doctors and healthcare professionals, a topic that matters directly to pharmacy students studying pharmaceutical marketing, ethics, and the Drugs and Magic Remedies Act framework.

For students, this is a live case study in pharma regulation and ethics. Marketing codes exist to prevent inducements and misleading promotion, and any revision could change how companies interact with prescribers and pharmacists. Watch for the panel's recommendations on enforcement, disclosure, and penalties, since these will shape compliant marketing practice across the Indian pharmaceutical industry.

CDSCO spurious drug alert: Sporlac-DS batch BDS25003 flagged as suspected spurious medicine

The Central Drugs Standard Control Organisation (CDSCO) has flagged batch BDS25003 of Lactic Acid Bacillus tablets, sold under the brand name Sporlac-DS, as purportedly spurious in its September 2026 alert. According to the alert, the label-claim manufacturer stated that it had not manufactured this batch, which is the classic red flag for a spurious or falsely labelled drug entering the supply chain.

This story is essential reading for pharmacy students on drug quality, spurious drugs, and pharmacovigilance. Spurious medicines undermine treatment, damage trust in the supply chain, and put patients at risk. Pharmacists play a frontline role here: verifying batch numbers, sourcing only from licensed suppliers, checking packaging and labelling, and reporting suspicious products to drug inspectors and CDSCO through the proper channels.

Pune cancer diagnostics breakthrough: CDSCO approves OncoDiscover, India's first CTC blood test

Pune-based company Actorius has announced that CDSCO has approved OncoDiscover, a blood test that detects circulating tumour cells (CTCs) using magnetic particles and fluorescence microscopy. The company claims it is India's first licence of its kind for this type of test. Circulating tumour cells are cancer cells that shed from a tumour into the bloodstream, and detecting them through a blood sample is an example of liquid biopsy, a fast-growing area of cancer diagnostics.

For pharmacy students, OncoDiscover connects pharmacology, oncology, and diagnostics in one story. Liquid biopsy and CTC testing support cancer monitoring and personalised treatment decisions, and pharmacists increasingly need to understand diagnostic tests alongside medicines. Students should also note the careful wording: the "first of its kind" claim comes from the company, and independent clinical validation and real-world use will determine how widely the test is adopted by oncologists across India.

Telangana pharma factory accident: two workers die in chloroform leak at Saraca Laboratories, Sangareddy

Two workers died and others fell ill after a chloroform vapour leak on 22 October at Saraca Laboratories in Sangareddy, Telangana. The Telangana Human Rights Commission has sought a report on the incident, with the report due by 26 November. Chloroform is a volatile chemical used in pharmaceutical manufacturing, and vapour exposure in enclosed industrial settings can be rapidly dangerous without proper ventilation, monitoring, and protective equipment.

This tragedy is a stark reminder that industrial pharmacy and pharmaceutical manufacturing safety are as important as drug discovery. Pharmacy students heading into production, quality assurance, or regulatory roles must understand good manufacturing practices (GMP), chemical handling, occupational safety, effluent and vapour controls, and emergency response. Every safety protocol in a pharma plant exists because of incidents like this one, and accountability through official inquiries is part of how the industry learns and improves.

China oncology research: Kelun-Biotech presents sac-TMT plus pembrolizumab Phase II data at ESMO 2026

Kelun-Biotech has presented Phase II results for sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab in advanced urothelial carcinoma at the European Society for Medical Oncology (ESMO) Congress 2026. Sac-TMT is an antibody-drug conjugate, a targeted therapy that delivers a cytotoxic payload directly to cancer cells, while pembrolizumab is an immunotherapy that helps the immune system recognise and attack cancer. In addition, two new sac-TMT indication applications have been accepted by China's National Medical Products Administration (NMPA).

For Indian pharmacy students, this story ties together antibody-drug conjugates, immunotherapy combinations, and global oncology trial design. Urothelial carcinoma, a cancer of the urinary tract lining, is an area of intense research, and combination strategies are being tested worldwide to improve outcomes. Following ESMO presentations and NMPA decisions also builds the habit of tracking international regulatory and clinical milestones that often reach Indian practice a few years later.

Russia HIV drug patent ruling: court grants Biokhimik licence to manufacture cabotegravir

A Moscow Region court has ordered ViiV Healthcare and Shionogi to grant Russian manufacturer Biokhimik a non-exclusive, Russia-only licence for cabotegravir patents, at combined royalties of 1.75 percent. The ruling is not yet in force. Cabotegravir is an antiretroviral medicine used in HIV treatment and prevention, and patent licensing decisions directly affect which companies can manufacture a medicine in a given country and at what cost.

This is a valuable lesson in pharmaceutical patents, compulsory-style licensing, and access to medicines. Patent law balances innovation incentives for originator companies against public health needs, and court-ordered licences are one of the most debated tools in that balance. Pharmacy students should follow whether the ruling takes effect and how it influences HIV medicine supply and pricing in Russia, since similar access debates play out in India and other countries as well.

World cell therapy safety news: BMS discloses patient death in multiple sclerosis CAR-T trial

Bristol Myers Squibb (BMS) has disclosed a patient death in its early-stage trial of zola-cel, a CAR-T cell therapy being studied in multiple sclerosis (MS). The patient died of septic pneumonia 44 days after infusion. CAR-T therapy involves engineering a patient's own immune cells to target disease, and while it has transformed some blood cancer treatments, its use in autoimmune conditions like multiple sclerosis is still experimental and carries serious infection and immune-related risks.

For pharmacy students, this disclosure underlines why clinical trial safety reporting and pharmacovigilance matter so much. Early-phase trials test both efficacy and safety, and serious adverse events, including deaths, must be transparently reported so that researchers, regulators, and ethics committees can judge whether a trial should continue, pause, or change. It is also a reminder that septic pneumonia and other infections are a known risk when the immune system is heavily modified, which is why patient monitoring after cell therapy infusion is so intensive.

Conclusion

Today's news covers the full arc of pharmacy: the rules that govern how medicines are marketed, the alerts that keep spurious drugs out of pharmacies, a new diagnostic tool from Pune, the human cost of industrial safety failures, cutting-edge cancer research from China, a patent ruling shaping HIV medicine access in Russia, and a safety disclosure that shows clinical research at its most honest and difficult. For pharmacy students, the lesson is clear: a good pharmacist is not only someone who knows drug names and doses, but someone who follows regulation, quality, safety, diagnostics, patents, and clinical evidence together. Keep reading primary sources, question company claims, and connect each headline back to the subjects you study, from pharmaceutical jurisprudence and pharmacology to pharmaceutics and clinical pharmacy. That habit is what turns daily news into lasting professional knowledge.

References

← All daily news